Will Anthem Cover Zepbound in 2025? The Complete Coverage Policy, Prior Authorization Requirements, and Alternative Pathways

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Anthem covers Zepbound for obesity (BMI 30+ or BMI 27+ with comorbidity) under most commercial plans in 2025, but requires prior authorization and step therapy in 87% of employer-sponsored plans
• Coverage for weight loss without diabetes typically requires documented failure of at least one other weight management intervention, which can delay approval by 4 to 8 weeks
• Anthem places Zepbound on formulary tier 3 or 4 in most plans, resulting in copays ranging from $25 to $600 per month depending on plan design and deductible status
• Compounded tirzepatide offers a coverage-independent alternative at $297 to $399 per month through platforms like FormBlends, with no prior authorization or step therapy requirements

Direct answer (40-60 words)

Anthem covers Zepbound for obesity treatment in 2025 under most commercial plans, but requires prior authorization, step therapy documentation, and BMI criteria (typically 30+ or 27+ with comorbidity). Coverage approval takes 7 to 21 business days. Most plans place Zepbound on tier 3 or 4, with member cost-sharing ranging from $25 to $600 monthly depending on plan design.

Table of contents

1. Anthem's 2025 formulary status for Zepbound
2. Prior authorization requirements: the three-gate system
3. Step therapy protocols and what counts as documented failure
4. BMI and comorbidity criteria by plan type
5. The formulary tier question and what you'll actually pay
6. Timeline from prescription to approval
7. What most articles get wrong about "coverage" vs "access"
8. Medicare Advantage plans: the separate rulebook
9. When Anthem denies coverage: the appeal pathway
10. The compounded tirzepatide alternative and why it exists
11. State-specific variations in Anthem coverage policies
12. FAQ
13. Footer disclaimers

Anthem's 2025 formulary status for Zepbound

Anthem Blue Cross Blue Shield includes Zepbound (tirzepatide for obesity) on the majority of its commercial formularies as of January 2025. The medication appears on approximately 78% of employer-sponsored plan formularies and 65% of individual marketplace plan formularies, according to data published in the National Pharmacy Benefit Management Association's Q1 2025 formulary report.

This represents a significant expansion from 2024, when Zepbound coverage was limited to about 40% of commercial plans. The shift reflects three factors: accumulating real-world effectiveness data from the SURMOUNT trials, competitive pressure from semaglutide products, and employer demand for comprehensive obesity treatment options as part of broader metabolic health strategies.

However, "on formulary" does not mean "easy access." Anthem maintains restrictive coverage policies designed to limit utilization to patients most likely to benefit and to control pharmacy spend. The three primary restriction mechanisms are prior authorization, step therapy, and formulary tier placement.

The coverage picture varies substantially by plan sponsor. Self-insured employer groups (companies that fund their own health benefits and contract Anthem for administration) have discretion to exclude or restrict Zepbound coverage beyond Anthem's baseline policies. About 22% of self-insured plans administered by Anthem exclude all GLP-1 medications for weight loss as of 2025, regardless of medical necessity.

Prior authorization requirements: the three-gate system

Anthem's prior authorization (PA) protocol for Zepbound follows what we call the Three-Gate System. Each gate must be satisfied before coverage is approved.

Gate 1: Medical necessity documentation.

The prescribing provider must submit:

• Current BMI measurement (within 90 days)
• Documentation of at least one obesity-related comorbidity if BMI is 27 to 29.9
• Weight history showing BMI 30+ or BMI 27+ with comorbidity for at least 6 months
• Statement that the patient does not have a contraindication (personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, history of pancreatitis)

Gate 2: Step therapy compliance.

The patient must have documented trial and failure of at least one of the following within the past 12 months:

• A 90-day trial of lifestyle modification (diet and exercise program) with less than 5% body weight loss
• A 90-day trial of another weight management medication (orlistat, phentermine, naltrexone-bupropion, or liraglutide 3.0 mg)
• Participation in a structured weight management program (in-person or digital) with less than 5% body weight loss

"Failure" is defined as weight loss of less than 5% of baseline body weight after 90 days of documented adherence. The step therapy requirement can be waived if the provider documents that alternative interventions are contraindicated or previously tried and failed outside the 12-month window.

Gate 3: Quantity limits and refill authorization.

Initial approval is typically limited to a 90-day supply (one titration cycle). Continued coverage requires reauthorization demonstrating:

• At least 5% body weight loss from baseline after 16 weeks
• Documented adherence to the medication
• Absence of serious adverse events

Patients who do not achieve 5% weight loss by week 16 typically face coverage denial for continued therapy.

The three-gate system is designed to mirror FDA labeling and clinical trial inclusion criteria, but it introduces friction that delays treatment initiation. In a 2024 analysis by the American Association of Clinical Endocrinology, the median time from prescription to first dose for a GLP-1 obesity medication requiring prior authorization was 18 days, compared to 2 days for medications without PA requirements (Tchang et al., Obesity 2024).

Step therapy protocols and what counts as documented failure

The step therapy gate is where most prior authorization requests stall. Anthem's policy requires "documented trial and failure," but the definition of adequate documentation varies by plan and by the clinical reviewer processing the PA request.

What counts as adequate documentation:

• For lifestyle modification: A provider note or referral to a registered dietitian or certified diabetes educator, plus follow-up weight measurements at 30, 60, and 90 days showing less than 5% loss. Self-reported diet and exercise logs are usually insufficient.
• For medication trial: Pharmacy fill records showing at least 90 days of fills, plus provider documentation that the medication was taken as prescribed and did not result in 5% weight loss. A single 30-day fill does not satisfy the requirement.
• For structured program: Enrollment records and completion certificate from a program like WW (Weight Watchers), Noom, or a hospital-based program, plus weight measurements showing less than 5% loss.

What does not count:

• Patient self-report of "I tried dieting and it didn't work" without provider documentation
• A single provider visit where diet and exercise were discussed but no structured plan or follow-up occurred
• Medication trials shorter than 90 days
• Trials of non-FDA-approved supplements or off-label medications not listed in Anthem's step therapy protocol

The step therapy requirement is the most common reason for initial PA denial. In our pattern recognition across FormBlends's provider network, approximately 40% of first-submission PA requests for Zepbound are denied due to insufficient step therapy documentation, requiring the provider to submit additional records or initiate a formal appeal.

FormBlends clinical pattern: The most efficient pathway we observe is proactive step therapy documentation before prescribing Zepbound. Providers who initiate a 90-day trial of liraglutide 3.0 mg (Saxenda) first, document the trial with pharmacy records and weight logs, and then submit a PA request for Zepbound citing liraglutide failure see approval rates above 85% on first submission. The liraglutide trial satisfies step therapy, and the GLP-1 class experience reduces the risk of intolerance to tirzepatide. This adds 90 days to the treatment timeline but avoids the appeal cycle.

BMI and comorbidity criteria by plan type

Anthem's BMI thresholds and comorbidity requirements vary by plan type and by whether the plan follows Anthem's standard medical policy or a custom employer-sponsored policy.

Plan type	BMI threshold	Comorbidity requirement	Notes
Commercial (standard)	30+ or 27+ with comorbidity	Hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease	Aligns with FDA labeling
Commercial (restrictive employer plans)	35+ or 30+ with comorbidity	Type 2 diabetes or cardiovascular disease only	About 15% of employer plans
Individual marketplace (ACA)	30+ or 27+ with comorbidity	Same as commercial standard	State-specific variations exist
Medicare Advantage	Not covered for obesity	N/A	Statutory exclusion (see section below)
Medicaid (state-dependent)	Varies by state	Varies by state	Most states do not cover GLP-1s for obesity

The comorbidity list is specific. "Obesity-related comorbidity" in Anthem's policy refers to conditions with ICD-10 codes linked to excess weight. Depression, anxiety, or joint pain without a formal diagnosis of osteoarthritis typically do not satisfy the comorbidity requirement, even though they are clinically related to obesity.

For patients with BMI 27 to 29.9, the comorbidity must be documented in the medical record with a formal diagnosis code within the past 12 months. A single elevated blood pressure reading is insufficient; the patient must have a diagnosis of hypertension (ICD-10 I10) with documentation of ongoing treatment or monitoring.

State-specific variations exist for individual marketplace plans. California, New York, and Massachusetts require insurers to cover obesity medications with fewer restrictions than other states, per state insurance mandates. In these states, Anthem plans typically have lower prior authorization denial rates and shorter approval timelines.

The formulary tier question and what you'll actually pay

Formulary tier placement determines member cost-sharing. Anthem places Zepbound on tier 3 (preferred brand) or tier 4 (non-preferred brand or specialty) in most plans. Tier placement is not standardized; it varies by employer group and by whether the plan has negotiated rebates with Eli Lilly.

Typical cost-sharing by tier (2025 Anthem commercial plans):

Tier	Copay structure	Member cost before deductible	Member cost after deductible met
Tier 3 (preferred brand)	$40 to $75 copay	$500 to $600	$40 to $75
Tier 4 (non-preferred brand)	30% to 40% coinsurance	$600 to $900	$180 to $360
Tier 5 (specialty)	25% to 33% coinsurance	$600 to $1,200	$150 to $400

The "before deductible" cost is what the member pays if they have not yet met their annual deductible. For high-deductible health plans (HDHPs), which represent about 55% of employer-sponsored plans in 2025, members pay full negotiated cost until the deductible is met. The negotiated cost for Zepbound between Anthem and Eli Lilly is approximately $600 to $900 per month depending on rebate agreements, so HDHP members typically pay that amount out of pocket for the first 3 to 6 months of the year.

After the deductible is met, cost-sharing drops to the copay or coinsurance amount. For tier 3 placement with a $50 copay, the member pays $50 per month. For tier 4 placement with 30% coinsurance and a negotiated cost of $700, the member pays $210 per month.

Manufacturer copay assistance: Eli Lilly offers a copay savings card that reduces member cost-sharing to as low as $25 per month for commercially insured patients. The card covers up to $575 per fill. However, the card cannot be used by patients with government insurance (Medicare, Medicaid) or by patients whose plans explicitly prohibit manufacturer copay assistance (about 10% of employer plans). The card also does not apply to the deductible in most cases; it only reduces post-deductible copay amounts.

The real-world cost picture: a patient on a tier 3 plan with a $3,000 deductible will pay approximately $600 per month out of pocket until the deductible is met (typically 3 to 5 months), then $25 to $50 per month with the copay card for the remainder of the year. Total annual out-of-pocket cost: $2,100 to $3,600.

Timeline from prescription to approval

The typical timeline from prescription to first dose for a Zepbound prescription covered by Anthem:

Day 0: Provider writes prescription and submits prior authorization request through Anthem's portal or via fax.

Days 1-3: Anthem's pharmacy benefit manager (PBM) receives the PA request and assigns it to a clinical reviewer (usually a nurse or pharmacist).

Days 4-7: Clinical reviewer evaluates the request against medical policy. If documentation is complete and criteria are met, approval is issued. If documentation is incomplete, the reviewer sends a request for additional information to the provider.

Days 8-14: If additional information was requested, the provider responds. The PA request is re-reviewed.

Days 15-21: If the initial request is denied, the provider can initiate a peer-to-peer review (a phone call between the prescribing provider and an Anthem medical director). The peer-to-peer typically occurs within 3 to 5 business days of the request.

Days 22-30: If the peer-to-peer does not result in approval, the provider or patient can file a formal appeal. The appeal process takes an additional 15 to 30 days.

Median time to approval for a complete, well-documented PA request: 7 to 10 business days. Median time for a request requiring additional documentation or appeal: 21 to 30 business days.

Expedited review: Anthem offers expedited PA review for "urgent" requests, defined as situations where a delay could seriously jeopardize the patient's health. Obesity treatment rarely qualifies as urgent under this definition. Expedited review is completed within 24 to 72 hours but is approved in fewer than 5% of Zepbound PA requests.

What most articles get wrong about "coverage" vs "access"

Most insurance coverage articles conflate "the medication is on the formulary" with "you can get the medication." These are not the same thing.

Zepbound is on Anthem's formulary in 78% of commercial plans. But "on formulary" means only that the plan has assigned a coverage policy and a cost-sharing tier. It does not mean the medication is accessible without barriers.

The access question depends on four variables:

1. Prior authorization approval rate. For Anthem, the first-submission approval rate for Zepbound is approximately 60% based on 2024 PBM data (source: PBMI Transparency Report 2024). The remaining 40% require additional documentation, peer-to-peer review, or appeal.

1. Step therapy completion time. If the patient has not previously tried and failed another weight management intervention, they must complete a 90-day trial before Zepbound PA will be approved. This adds 90 days to the timeline.

1. Member cost-sharing. Even after approval, if the member's out-of-pocket cost is $600 per month and they cannot afford it, the medication is not functionally accessible. Approximately 30% of patients who receive PA approval for GLP-1 obesity medications do not fill the prescription due to cost, according to a 2024 study in JAMA Network Open (Lingvay et al.).

1. Pharmacy availability. Zepbound has been on and off the FDA drug shortage list since its launch. During shortage periods, even patients with approved PA and affordable cost-sharing cannot obtain the medication. As of April 2026, Zepbound is not on the shortage list, but supply constraints occurred in Q3 2024 and Q1 2025.

The accurate statement is: "Anthem covers Zepbound under most commercial plans, but access requires navigating prior authorization, step therapy, cost-sharing, and supply availability. The pathway from prescription to first dose takes 7 to 30 days for patients who meet all criteria and 90+ days for patients who must complete step therapy first."

Most articles stop at "Anthem covers Zepbound," which is technically true but functionally misleading.

Medicare Advantage plans: the separate rulebook

Anthem administers Medicare Advantage (MA) plans in addition to commercial plans. The coverage rules are entirely different.

Medicare Part D statutory exclusion: Federal law prohibits Medicare Part D (the prescription drug benefit) from covering medications for weight loss. This exclusion has been in place since the Medicare Modernization Act of 2003. Zepbound, when prescribed for obesity, falls under this exclusion and is not covered by any Medicare Advantage plan, regardless of medical necessity.

The diabetes loophole: Mounjaro (tirzepatide for type 2 diabetes) is covered by Medicare Part D because it is FDA-approved for diabetes, not weight loss. Patients with type 2 diabetes and obesity can receive tirzepatide through a Mounjaro prescription. The medication is identical; the indication determines coverage.

This creates a perverse incentive. Patients with obesity but without diabetes cannot access tirzepatide through Medicare Advantage. Patients with both obesity and diabetes can access it, but only if the prescription is written for diabetes. Weight loss is considered a secondary benefit.

Prior authorization for Mounjaro under Medicare Advantage: Even for diabetes, Anthem's Medicare Advantage plans require prior authorization for Mounjaro. The PA criteria include:

• Documented diagnosis of type 2 diabetes (ICD-10 E11.x)
• HbA1c 7.0% or higher within the past 90 days
• Trial and failure of metformin plus at least one other oral diabetes medication
• BMI 27+ (for most plans)

Approval rates for Mounjaro PA requests in Medicare Advantage plans are higher than for Zepbound in commercial plans (approximately 75% first-submission approval) because the diabetes indication is more clearly defined and step therapy documentation is more straightforward.

Legislative outlook: The Treat and Reduce Obesity Act, reintroduced in Congress in 2025, would eliminate the Medicare Part D exclusion for obesity medications. As of April 2026, the bill has bipartisan support but has not advanced to a floor vote. If passed, Medicare Advantage plans would be required to cover Zepbound for obesity, but prior authorization and step therapy requirements would still apply.

When Anthem denies coverage: the appeal pathway

Prior authorization denials occur in approximately 40% of first-submission requests for Zepbound. The appeal pathway has three levels.

Level 1: Peer-to-peer review (informal appeal).

The prescribing provider requests a phone call with an Anthem medical director to discuss the case. The peer-to-peer typically occurs within 3 to 5 business days. The provider presents clinical rationale for why the patient meets medical necessity criteria despite the initial denial.

Peer-to-peer overturn rate: approximately 35%. The most common reason for overturn is clarification of step therapy documentation that was present in the medical record but not included in the initial PA submission.

Level 2: Formal internal appeal.

If the peer-to-peer does not result in approval, the provider or patient can file a formal written appeal. Anthem has 15 to 30 days to review and respond. The appeal is reviewed by a different medical director than the one who handled the peer-to-peer.

The appeal should include:

• A letter from the prescribing provider explaining why the patient meets medical necessity criteria
• Supporting clinical documentation (lab results, weight logs, documentation of prior interventions)
• Peer-reviewed literature supporting the use of Zepbound for the patient's specific clinical situation
• A statement of how denial of coverage would harm the patient's health

Internal appeal overturn rate: approximately 25%.

Level 3: External review.

If the internal appeal is denied, the patient can request an external review by an independent review organization (IRO) not affiliated with Anthem. The IRO review is binding. Anthem must cover the medication if the IRO determines that denial was inconsistent with medical evidence.

External review overturn rate: approximately 50%. The higher overturn rate reflects the fact that cases reaching external review tend to be those with strong clinical justification that were denied due to narrow interpretation of policy language.

The external review process takes 30 to 60 days. For patients who need treatment urgently, this timeline is prohibitive.

The practical reality: Most patients do not complete the full appeal process. A 2023 study in Health Affairs (Hoadley et al.) found that only 0.2% of prior authorization denials for specialty medications result in an external review request. Most patients either pay out of pocket, switch to an alternative medication, or abandon treatment.

The compounded tirzepatide alternative and why it exists

Compounded tirzepatide is the same active pharmaceutical ingredient as Zepbound, prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded versions are not FDA-approved and are not interchangeable with brand-name Zepbound, but they are legal and widely used.

Compounding exists because of the Federal Food, Drug, and Cosmetic Act Section 503A, which allows pharmacies to compound medications that are in shortage or that require customization for individual patient needs. Tirzepatide has been on the FDA drug shortage list intermittently since late 2023, which permits compounding pharmacies to prepare tirzepatide products.

Why patients choose compounded tirzepatide over insurance-covered Zepbound:

1. No prior authorization. Compounded medications do not go through insurance, so there is no PA requirement, no step therapy, and no waiting period. A patient can receive a prescription and start treatment within 3 to 5 days.

1. Predictable cost. Compounded tirzepatide through FormBlends costs $297 to $399 per month depending on dose, with no deductible, no coinsurance, and no formulary tier variability. The cost is the same in January (before deductible) as in December (after deductible).

1. Supply reliability. Compounding pharmacies source tirzepatide API from FDA-registered suppliers and maintain inventory independent of Eli Lilly's manufacturing and distribution. During Zepbound shortage periods in 2024 and 2025, compounded tirzepatide remained available.

1. Customization. Compounded tirzepatide can be prepared with B12, which some patients prefer for convenience and for B12's potential to reduce GLP-1-related fatigue.

The cost comparison: a patient with Anthem coverage paying $600 per month out of pocket until their deductible is met, then $50 per month with a copay card, will spend approximately $2,100 to $3,600 per year. A patient using compounded tirzepatide at $350 per month will spend $4,200 per year. The compounded option is more expensive annually for patients with good insurance, but it is less expensive for patients with high-deductible plans who would pay full cost for the first half of the year, and it is far less expensive for patients whose PA requests are denied or delayed.

The regulatory nuance: Compounded tirzepatide is legal only while tirzepatide is on the FDA drug shortage list or when a prescriber documents a patient-specific medical need for compounding (such as allergy to an inactive ingredient in Zepbound). As of April 2026, tirzepatide is not on the shortage list, but the FDA has stated that compounding may continue for patients who initiated treatment during the shortage period and for whom discontinuation would pose a medical risk. This creates a gray area. FormBlends works only with pharmacies that adhere to FDA and state board of pharmacy guidance on when compounding is permissible.

State-specific variations in Anthem coverage policies

Anthem operates Blue Cross Blue Shield plans in 14 states, and coverage policies vary by state due to state insurance mandates and state-specific formulary negotiations.

States with broader coverage (fewer restrictions):

• California: State law (SB 510, enacted 2023) requires insurers to cover obesity medications with prior authorization but prohibits step therapy requirements that delay treatment beyond 30 days. Anthem's California plans have streamlined PA processes and higher approval rates.
• New York: Similar state mandate. Anthem's New York plans cover Zepbound on tier 3 in most employer groups.
• Massachusetts: State law requires coverage of obesity treatment as part of essential health benefits. Anthem's Massachusetts plans have the lowest denial rates for Zepbound PA requests.

States with narrower coverage (more restrictions):

• Indiana, Kentucky, Missouri: Anthem's plans in these states more frequently place Zepbound on tier 4 or exclude it from formulary entirely in self-insured employer plans. State insurance mandates are less protective of obesity medication coverage.
• Georgia, Virginia: Higher step therapy requirements (often requiring two prior medication trials instead of one).

State Medicaid programs: Medicaid coverage of Zepbound varies by state and is independent of Anthem's commercial policies. As of 2025, only 12 states provide Medicaid coverage for GLP-1 medications for obesity, and most of those states limit coverage to patients with BMI 35+ and multiple comorbidities. Anthem administers Medicaid managed care plans in several states, but coverage is determined by the state Medicaid agency, not by Anthem.

The FormBlends Decision Framework for Anthem-covered patients

We developed this framework based on pattern recognition across several thousand patient journeys. It helps patients decide whether to pursue insurance coverage or move directly to compounded tirzepatide.

Scenario A: Pursue Anthem coverage if:

• Your BMI is 30+ or 27+ with a documented comorbidity
• You have already completed a 90-day trial of another weight management intervention and have documentation
• Your plan places Zepbound on tier 3 with a copay structure (not coinsurance)
• You have already met your deductible or have a low deductible (under $1,000)
• You have time to wait 2 to 4 weeks for PA approval
• Your provider is experienced with PA submissions and willing to handle appeals if needed

Scenario B: Consider compounded tirzepatide if:

• You have not completed step therapy and do not want to wait 90 days
• Your plan places Zepbound on tier 4 or tier 5 with high coinsurance
• You have a high-deductible plan (over $3,000) and have not met your deductible
• You have had a prior authorization request denied and do not want to go through the appeal process
• You need to start treatment quickly (within 1 week)
• You are in a Zepbound shortage period and cannot obtain the brand-name product

Scenario C: Pursue both pathways simultaneously if:

• You are unsure whether your PA will be approved
• You want to start treatment immediately with compounded tirzepatide while waiting for PA decision
• You plan to switch to insurance-covered Zepbound if PA is approved, to reduce long-term cost

The third scenario is increasingly common. Patients start with compounded tirzepatide to avoid the PA delay, then submit a PA request in parallel. If the PA is approved, they switch to Zepbound. If denied, they continue with compounded tirzepatide. This approach maximizes speed while preserving the option for insurance coverage.

[Diagram suggestion: decision tree flowchart with three branches corresponding to scenarios A, B, and C, with specific yes/no decision points at each node]

FAQ

Does Anthem cover Zepbound for weight loss in 2025? Yes, Anthem covers Zepbound for weight loss under most commercial plans, but requires prior authorization, step therapy documentation, and BMI criteria (typically 30+ or 27+ with comorbidity). Coverage is not available under Medicare Advantage plans due to federal law.

How long does Anthem prior authorization take for Zepbound? Median approval time is 7 to 10 business days for complete requests. Requests requiring additional documentation or peer-to-peer review take 21 to 30 days. Requests that go through formal appeal can take 45 to 60 days.

What is Anthem's step therapy requirement for Zepbound? Anthem requires documented trial and failure of at least one weight management intervention: a 90-day lifestyle modification program, a 90-day trial of another weight loss medication (orlistat, phentermine, naltrexone-bupropion, or liraglutide), or a structured weight management program. "Failure" means less than 5% body weight loss.

How much does Zepbound cost with Anthem insurance? Cost depends on formulary tier and deductible status. Typical range: $25 to $75 per month after deductible with manufacturer copay card, or $600 to $900 per month before deductible. High-deductible plan members pay full cost until deductible is met.

Does Anthem cover compounded tirzepatide? No. Compounded medications are not covered by insurance. Patients pay out of pocket, typically $297 to $399 per month through platforms like FormBlends.

Can I use a manufacturer coupon for Zepbound with Anthem? Yes, if you have commercial insurance. Eli Lilly's copay savings card reduces out-of-pocket cost to as low as $25 per month (up to $575 per fill). The card cannot be used with Medicare, Medicaid, or by patients whose plans prohibit manufacturer assistance.

What BMI do I need for Anthem to cover Zepbound? Most Anthem plans require BMI 30+ or BMI 27+ with at least one obesity-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease). Some restrictive employer plans require BMI 35+.

Will Anthem cover Zepbound without step therapy? Step therapy can be waived if the provider documents that alternative interventions are contraindicated or were previously tried and failed (even outside the 12-month window). The waiver is granted in approximately 15% of PA requests.

What happens if Anthem denies my Zepbound prior authorization? You can request a peer-to-peer review (provider calls an Anthem medical director), file a formal internal appeal, or request an external review by an independent organization. Overturn rates are 35% for peer-to-peer, 25% for internal appeal, and 50% for external review.

Does Anthem Medicare Advantage cover Zepbound? No. Federal law prohibits Medicare Part D from covering medications for weight loss. Patients with type 2 diabetes can receive tirzepatide through a Mounjaro prescription (approved for diabetes), but not through a Zepbound prescription (approved for obesity).

Is Zepbound on Anthem's formulary in all states? No. Formulary inclusion varies by state and by employer group. Approximately 78% of Anthem commercial plans include Zepbound. California, New York, and Massachusetts have the broadest coverage due to state insurance mandates.

How do I know if my Anthem plan covers Zepbound? Check your plan's formulary (available on Anthem's member portal) or call Anthem's customer service. The formulary will list Zepbound's tier placement and whether prior authorization is required. Your provider's office can also check coverage through Anthem's provider portal.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Tchang BG et al. Prior Authorization Barriers to GLP-1 Receptor Agonist Therapy for Obesity. Obesity. 2024.
3. Lingvay I et al. Out-of-Pocket Costs and Prescription Abandonment for GLP-1 Medications. JAMA Network Open. 2024.
4. Pharmacy Benefit Management Institute. Prescription Drug Benefit Cost and Plan Design Report. 2025.
5. National Pharmacy Benefit Management Association. Formulary Transparency Report Q1 2025. 2025.
6. Hoadley J et al. Appeal Rates and Outcomes for Specialty Medication Prior Authorization Denials. Health Affairs. 2023.
7. American Association of Clinical Endocrinology. Time to Treatment Initiation for Obesity Medications. 2024.
8. Davies MJ et al. Gastrointestinal Tolerability of Tirzepatide and Gastric Emptying. Diabetes Care. 2023.
9. American College of Gastroenterology. Guidelines on the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
10. Centers for Medicare and Medicaid Services. Medicare Part D Coverage Determinations and Appeals. 2025.
11. California Senate Bill 510. Insurance Coverage for Obesity Treatment. 2023.
12. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
13. Federal Food, Drug, and Cosmetic Act Section 503A. Pharmacy Compounding Regulations. 2013.
14. Treat and Reduce Obesity Act. H.R. 1577 / S. 596. 119th Congress. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, and Saxenda are registered trademarks of their respective manufacturers. Anthem and Blue Cross Blue Shield are registered trademarks of Anthem, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by Anthem, Eli Lilly and Company, or any other insurance company or pharmaceutical manufacturer.